Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound

Petrović, Gordana; Bjelaković, Goran; Benedeto-Stojanov, Daniela; Nagorni, Aleksandar; Brzački, Vesna; Marković-Živković, Bojana

doi:10.2298/vsp150514093p

Cited by 17 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dyslipidaemia is a well-established risk factor for NAFLD. 62 In fact, patients with NAFLD usually have an atherogenic dyslipidaemia characterised by high levels of TG, LDL cholesterol and VLDL cholesterol, as well as a higher concentration of remnant lipoprotein cholesterol coupled with low HDL cholesterol levels. 63 64 In this context, due to an increased cardiovascular risk, the treatment of dyslipidaemia should be considered in the management framework of NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

Маев

Самсонов

Пальгова

et al. 2020

BMJ Open Gastroenterol

View full text Add to dashboard Cite

ObjectiveNon-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal results of liver function tests. Earlier research showed that polyenylphosphatidylcholine (PPC) has hepatoprotective effects and thus can be used for the treatment of NAFLD and the prevention of its progression. Accordingly, the aim of this observational study was to evaluate if PPC administered as adjunctive therapy in routine clinical practice can effectively improve liver function tests of NAFLD in Russian patients with associated metabolic comorbidities.DesignA total of 2843 adult patients with newly diagnosed NAFLD, who had a least one of four comorbidities, namely, overweight/obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolaemia, and who were prescribed 1.8 g/day of PPC as an adjunctive treatment to standard care, were enrolled during 2015–2016. Laboratory data were collected at baseline and 12 and 24 weeks of the study, and included liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT)), fasting plasma glucose, and lipid profile.ResultsOverall, 2263 patients (79.6%) had at least two metabolic comorbidities associated with NAFLD, and overweight/obesity was the most common comorbidity reported in 2298 (80.8%) patients. At 24 weeks, there was a significant decrease in liver enzyme levels (all p<0.001 compared with baseline). Across the four comorbidity subgroups, there was a mean drop of ALT levels ranging from 19.7 to 22.0 U/L, AST from 16.9 to 18.4 U/L, and GGT from 17.2 to 18.7 U/L. Similar findings were reported in subgroups with either one, two, three, or four comorbidities, with a significant decrease in liver enzyme levels ranging from 18.4 to 22.4 U/L for ALT, 14.8 to 18.7 U/L for AST, and 15.5 to 19.5 U/L for GGT.ConclusionsAdjuvant treatment with PPC resulted in consistent improvements in liver enzymes in patients with newly diagnosed NAFLD and associated metabolic comorbidities.Trial registration numberNCT00063622.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

Маев

Самсонов

Пальгова

et al. 2020

BMJ Open Gastroenterol

View full text Add to dashboard Cite

show abstract

“…There are 39% of women and 39% of men aged ≥18 overweight and 18% of overweight or obese children and adolescents in 2016 [2]. Insulin resistance and dyslipidemia induced by obesity and diabetes are risk factors for the occurrence of nonalcoholic fatty liver disease (NAFLD) [3,4]. How to prevent and improve obesity and diabetes has become an important issue to reduce the prevalence of NAFLD.…”

Section: Introductionmentioning

confidence: 99%

Functional Comparison of High and Low Molecular Weight Chitosan on Lipid Metabolism and Signals in High-Fat Diet-Fed Rats

et al. 2018

View full text Add to dashboard Cite

The present study examined and compared the effects of low- and high-molecular weight (MW) chitosan, a nutraceutical, on lipid metabolism in the intestine and liver of high-fat (HF) diet-fed rats. High-MW chitosan as well as low-MW chitosan decreased liver weight, elongated the small intestine, improved the dysregulation of blood lipids and liver fat accumulation, and increased fecal lipid excretion in rats fed with HF diets. Supplementation of both high- and low-MW chitosan markedly inhibited the suppressed phosphorylated adenosine monophosphate (AMP)-activated protein kinase-α (AMPKα) and peroxisome proliferator-activated receptor-α (PPARα) protein expressions, and the increased lipogenesis/cholesterogenesis-associated protein expressions [peroxisome proliferator-activated receptor-γ (PPARγ), sterol regulatory element binding protein-1c and -2 (SREBP1c and SREBP2)] and the suppressed apolipoprotein E (ApoE) and microsomal triglyceride transfer protein (MTTP) protein expressions in the livers of rats fed with HF diets. Supplementation with both a low- and high-MW chitosan could also suppress the increased MTTP protein expression and the decreased angiopoietin-like protein-4 (Angptl4) expression in the intestines of rats fed with HF diets. In comparison between low- and high-MW chitosan, high-MW chitosan exhibits a higher efficiency than low-MW chitosan on the inhibition of intestinal lipid absorption and an increase of hepatic fatty acid oxidation, which can improve liver lipid biosynthesis and accumulation.

show abstract

“…A positive association was observed between red meat and NAFLD in males, perhaps it is because males had a higher meat intakes and a higher prevalence of fatty liver than females [39]. Moreover, several studies had found signi cant associations of high meat intakes with obesity, type 2 diabetes and hypertension [14,17,40], which were considered as risk factors in the development of NAFLD [19,41,42]. In our study, positive association of red meat intake with NAFLD was found in people with BMI≥24 kg/m 2 and people with hypertension.…”

Section: Discussionmentioning

confidence: 99%

Association of Meat Consumption With NAFLD Risk and Liver-related Biomarkers in Older Chinese: A Cross-sectional Study

Peng

Xie

Pan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: High meats intake contributes to unhealthy status. The present study aims to evaluate the association of meat consumption with non-alcohol fatty liver disease (NAFLD) risk and liver-related biomarkers in middle-aged and elderly Chinese.Methods: A cross-sectional study was conducted in individuals who were 45 years or older and underwent physical examination from April 2015 to August 2017 in Southeast China. NAFLD was evaluated by abdominal ultrasonography. Results: High consumptions of red meat (28.44-49.74 and >71.00 g/day) was positively associated with NAFLD risk on inverse probability of treatment weighting analysis, adjusting for smoking, tea intake, weekly hours of physical activity and presence of hypertension, dyslipidemia and diabetes (ORadjusted=1.948 and 1.1.716, respectively). Exposure-response relationship analysis presented that red meat intake was positively associated with NAFLD risk. Significant associations of red meat intakes with serum levels of γ-glutamyl transferase, alanine transaminase, aspartate aminotransferase, total triglyceride and high-density lipoprotein cholesterol were found (rs=0.176, 0.128, 0.060, 0.085 and -0.074, respectively). Conclusions: These findings suggest that reduction of meat consumption may decrease NAFLD risk and should warrant further investigations. Meat consumptions were measured by a semi-quantitative food frequency questionnaire.

show abstract

Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound

Abstract: The results of our study have confirmed that a high percentage of patients with high risk factors (DM, MS, dyslipidemia, hypertension) have NAFLD.

Cited by 17 publications

References 43 publications

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

Functional Comparison of High and Low Molecular Weight Chitosan on Lipid Metabolism and Signals in High-Fat Diet-Fed Rats

Association of Meat Consumption With NAFLD Risk and Liver-related Biomarkers in Older Chinese: A Cross-sectional Study

Contact Info

Product

Resources

About

Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound

Abstract: The results of our study have confirmed that a high percentage of patients with high risk factors (DM, MS, dyslipidemia, hypertension) have NAFLD.

Cited by 17 publications

References 43 publications

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

Functional Comparison of High and Low Molecular Weight Chitosan on Lipid Metabolism and Signals in High-Fat Diet-Fed Rats

Association of Meat Consumption With NAFLD&nbsp;Risk and Liver-related Biomarkers in Older Chinese: A Cross-sectional Study

Contact Info

Product

Resources

About

Association of Meat Consumption With NAFLD Risk and Liver-related Biomarkers in Older Chinese: A Cross-sectional Study